Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 plus toripalimab and chemotherapy in advanced lung cancer
CTR20222776Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tifcemalimab in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Oct 2022; status: completed.
02
Drugs
tifcemalimab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20222776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222776.